Skip to main content
padlock icon - secure page this page is secure

Anti‐CD19 chimeric antigen receptor‐modified T cells for B‐cell malignancies: a systematic review of efficacy and safety in clinical trials

Buy Article:

$59.00 + tax (Refund Policy)

Administration of anti‐CD19 chimeric antigen receptor (CAR)‐modified T cells for B‐cell malignancies has been remarkably effective in recent clinical trials. To investigate the critical parameters affecting efficacy and evaluated the safety of using CAR T cells targeting CD19 in B‐lineage malignancies. We performed a systematic review of reported phase I clinical trials using CAR T cells targeting CD19 in B‐lineage malignancies.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: B‐cell malignancy; CD19; chimeric antigen receptor; survival analysis

Document Type: Research Article

Publication date: April 1, 2016

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more